Argent Biopharma Limited has released a press release.
Patent Granted for CannEpiL SNEDDS
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- March 2022 Quarterly Activity and Cash Flow Reports
- Patent Granted for CimetrA
- Sciensus Rare EU & UK Sales and Distribution Agreement
- Response to ASX Query
- ArtemiC receives Indian importation and sales approval
Later from Argent Biopharma
- Response to ASX Aware Query
- Cognicann Clinical Trial Results
- Glioblastoma pre-clinical trial results
- CimetrA anti-inflammatory pre-clinical study results
- Approvals received for South African CimetrA Clinical Trial
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma